Targeted-release Budesonide (Nefecon) versus systemic glucocorticoids for IgA nephropathy: a placebo-anchored indirect treatment comparison of randomized controlled trials

Jianbo Qing, Wenjie Wei, Junnan Wu · 2026

Read Targeted-release Budesonide (Nefecon) versus systemic glucocorticoids for IgA nephropathy: a placebo-anchored indirect treatment comparison of randomized controlled trials by Jianbo Qing, Wenjie Wei, Junnan Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13621531.txt.

Description

BackgroundIgA nephropathy (IgAN) is a leading cause of end-stage renal disease, particularly in East Asia. Although systemic glucocorticoids are commonly used to delay progression, they are associated with significant adverse effects. Targeted-release budesonide (Nefecon) offers localized immunosuppression, targeting the gut-associated lymphoid tissue (Peyer’s patches), with the aim of reducing systemic exposure.

Catalog record

CREATORJianbo Qing, Wenjie Wei, Junnan Wu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13621531

Browse the full library · About the Tower of Babel